Colony Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $4.57M | Sell |
40,649
-794
| -2% | -$89.3K | 0.07% | 226 |
|
|
2023
Q2 | $3.91M | Buy |
41,443
+19
| +0% | +$1.79K | 0.06% | 257 |
|
|
2023
Q1 | $4.19M | Buy |
41,424
+33,069
| +396% | +$3.35M | 0.06% | 244 |
|
|
2022
Q4 | $998K | Buy |
8,355
+1,445
| +21% | +$173K | 0.01% | 485 |
|
|
2022
Q3 | $734K | Sell |
6,910
-2
| -0% | -$212 | 0.01% | 502 |
|
|
2022
Q2 | $674K | Buy |
6,912
+2
| +0% | +$195 | 0.01% | 537 |
|
|
2022
Q1 | $648K | Sell |
6,910
-195
| -3% | -$18.3K | 0.01% | 570 |
|
|
2021
Q4 | $605K | Sell |
7,105
-447
| -6% | -$38.1K | 0.01% | 549 |
|
|
2021
Q3 | $724K | Hold |
7,552
| – | – | 0.01% | 488 |
|
|
2021
Q2 | $735K | Hold |
7,552
| – | – | 0.01% | 443 |
|
|
2021
Q1 | $734K | Buy |
7,552
+377
| +5% | +$36.6K | 0.02% | 448 |
|
|
2020
Q4 | $688K | Sell |
7,175
-1,343
| -16% | -$129K | 0.02% | 430 |
|
|
2020
Q3 | $819K | Sell |
8,518
-617
| -7% | -$59.3K | 0.02% | 388 |
|
|
2020
Q2 | $1.11M | Sell |
9,135
-58
| -0.6% | -$7.07K | 0.03% | 331 |
|
|
2020
Q1 | $796K | Sell |
9,193
-813
| -8% | -$70.4K | 0.03% | 377 |
|
|
2019
Q4 | $1.08M | Sell |
10,006
-5,789
| -37% | -$623K | 0.03% | 395 |
|
|
2019
Q3 | $1.42M | Sell |
15,795
-1,103
| -7% | -$99.4K | 0.05% | 315 |
|
|
2019
Q2 | $1.43M | Buy |
+16,898
| New | +$1.43M | 0.05% | 319 |
|